Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$25.06 -8.6%	$27.10	$20.84 ▼ $37.49	$2.10B	1.91	1.21 million shs	1.85 million shs
CRSP CRISPR Therapeutics	$41.99 -3.4%	$43.02	$36.52 ▼ $75.91	$3.60B	1.77	2.23 million shs	1.19 million shs
NTLA Intellia Therapeutics	$9.22 -4.2%	$10.48	$8.30 ▼ $28.54	$954.43M	1.97	3.29 million shs	2.08 million shs
VRTX Vertex Pharmaceuticals	$502.92 +1.5%	$453.85	$377.85 ▼ $519.88	$129.14B	0.41	1.49 million shs	1.70 million shs

Unlock the Potential in Options Trading

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+3.79%	+5.02%	+3.20%	-2.28%	-23.41%
CRSP CRISPR Therapeutics	+2.64%	-0.80%	+10.35%	-4.21%	-42.24%
NTLA Intellia Therapeutics	+3.44%	+2.78%	+0.42%	-29.06%	-65.37%
VRTX Vertex Pharmaceuticals	+1.45%	+0.77%	+5.42%	+6.74%	+20.12%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	3.1129 of 5 stars	4.5	1.0	0.0	2.5	2.5	0.6
CRSP CRISPR Therapeutics	3.1879 of 5 stars	4.2	1.0	0.0	2.7	3.3	0.6
NTLA Intellia Therapeutics	4.4363 of 5 stars	4.3	1.0	4.7	1.9	2.5	1.3
VRTX Vertex Pharmaceuticals	3.8047 of 5 stars	2.3	3.0	3.3	2.9	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$50.82	102.79% Upside
CRSP CRISPR Therapeutics	2.48	Hold	$73.11	74.10% Upside
NTLA Intellia Therapeutics	2.63	Moderate Buy	$37.56	307.33% Upside
VRTX Vertex Pharmaceuticals	2.65	Moderate Buy	$506.70	0.75% Upside

Current Analyst Ratings Breakdown

Latest CRSP, VRTX, NTLA, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/12/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/10/2025	BEAM Beam Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$34.00
3/10/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/10/2025	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$57.00
3/10/2025	BEAM Beam Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$40.00
3/5/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
3/4/2025	NTLA Intellia Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$90.00 ➝ $50.00
3/3/2025	BEAM Beam Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$24.00 ➝ $25.00
2/28/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
2/28/2025	NTLA Intellia Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $26.00
2/28/2025	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $14.00

(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	33.02	N/A	N/A	$12.04 per share	2.08
CRSP CRISPR Therapeutics	$35M	102.90	N/A	N/A	$22.52 per share	1.86
NTLA Intellia Therapeutics	$57.88M	16.49	N/A	N/A	$11.73 per share	0.79
VRTX Vertex Pharmaceuticals	$11.02B	11.72	N/A	N/A	$63.90 per share	7.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$132.53M	-$4.58	N/A	N/A	N/A	-41.07%	-16.22%	-10.94%	5/6/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.37	N/A	N/A	N/A	-981.54%	-18.46%	-15.79%	5/14/2025 (Estimated)
NTLA Intellia Therapeutics	-$481.19M	-$5.25	N/A	N/A	N/A	N/A	-49.34%	-40.27%	5/8/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$2.20	N/A	28.72	2.11	-4.86%	-2.02%	-1.49%	5/5/2025 (Estimated)

Latest CRSP, VRTX, NTLA, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/25/2025	Q4 2024	BEAM Beam Therapeutics	-$1.25	-$1.09	+$0.16	-$1.09	$16.47 million	$30.00 million
2/11/2025	Q4 2024	CRSP CRISPR Therapeutics	-$1.15	-$0.44	+$0.71	-$0.44	N/A	N/A
2/10/2025	Q4 2024	VRTX Vertex Pharmaceuticals	$3.99	$3.54	-$0.45	$3.50	$2.78 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	3.59%	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	5.69	5.69
CRSP CRISPR Therapeutics	N/A	22.07	22.07
NTLA Intellia Therapeutics	N/A	6.73	6.73
VRTX Vertex Pharmaceuticals	0.01	2.69	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CRSP CRISPR Therapeutics	69.20%
NTLA Intellia Therapeutics	88.77%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	4.20%
CRSP CRISPR Therapeutics	4.10%
NTLA Intellia Therapeutics	3.20%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	83.69 million	79.33 million	Optionable
CRSP CRISPR Therapeutics	473	85.77 million	82.26 million	Optionable
NTLA Intellia Therapeutics	600	103.52 million	98.59 million	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.79 million	256.28 million	Optionable

CRSP, VRTX, NTLA, and BEAM Headlines

Recent News About These Companies

David Altshuler Sells 3,231 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock

March 13 at 4:23 PM | marketbeat.com

GILD vs. VRTX: Which Stock Is the Better Value Option?

March 13 at 1:09 PM | zacks.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Jupiter Asset Management Ltd.

March 13 at 7:41 AM | marketbeat.com

Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Sells 3,231 Shares of Stock

March 13 at 6:56 AM | insidertrades.com

Tredje AP fonden Has $55.35 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 13 at 5:49 AM | marketbeat.com

Vestcor Inc Sells 12,624 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 13 at 5:48 AM | marketbeat.com

Swiss National Bank Cuts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 13 at 5:39 AM | marketbeat.com

630 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Natural Investments LLC

March 13 at 4:35 AM | marketbeat.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded at StockNews.com

March 12 at 11:14 PM | marketbeat.com

Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know

March 12 at 8:42 PM | msn.com

Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report?

March 12 at 3:40 PM | msn.com

Why Vertex Pharmaceuticals Incorporated (VRTX) is the Best Pharma Stock to Buy According to Hedge Funds

March 12 at 2:57 PM | insidermonkey.com

Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio?

March 12 at 9:35 AM | insidermonkey.com

15,528 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by Wealth High Governance Capital Ltda

March 12 at 6:22 AM | marketbeat.com

Wealthfront Advisers LLC Buys 32,997 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 12 at 5:43 AM | marketbeat.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to "Buy" at StockNews.com

March 12 at 4:09 AM | americanbankingnews.com

11 Best Pharma Stocks to Buy According to Hedge Funds

March 11 at 9:20 PM | insidermonkey.com

3 Reasons to Avoid VRTX and 1 Stock to Buy Instead

March 11 at 4:18 PM | finance.yahoo.com

Citizens Financial Group Inc. RI Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 11 at 6:02 AM | marketbeat.com

Nasdaq Correction: The 2 Smartest Stocks to Buy and Hold Forever

March 11 at 5:31 AM | fool.com

Clare Market Investments LLC Acquires New Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 11 at 5:25 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP, VRTX, NTLA, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$25.06 -2.36 (-8.61%)

Closing price 04:00 PM Eastern

Extended Trading

$25.02 -0.04 (-0.14%)

As of 05:33 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$41.99 -1.50 (-3.45%)

Closing price 04:00 PM Eastern

Extended Trading

$42.04 +0.04 (+0.11%)

As of 05:44 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Intellia Therapeutics NASDAQ:NTLA

$9.22 -0.40 (-4.16%)

Closing price 04:00 PM Eastern

Extended Trading

$9.27 +0.05 (+0.53%)

As of 05:47 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Vertex Pharmaceuticals NASDAQ:VRTX

$502.92 +7.50 (+1.51%)

Closing price 04:00 PM Eastern

Extended Trading

$506.46 +3.54 (+0.70%)

As of 05:44 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time